Spatial and temporal organization of signal transduction is essential in determining the speed and precision by which signaling events occur. Adaptor proteins are key to organizing signaling enzymes near their select substrates and away from others in order to optimize precision and speed of response. Here, we describe the role of adaptor proteins in determining the speci®c function of individual protein kinase C (PKC) isozymes. These isozymeselective proteins were called collectively RACKs (receptors for activated C-kinase). The role of RACKs in PKC-mediated signaling was determined using isozyme-speci®c inhibitors and activators of the binding of each isozyme to its respective RACK. In addition to anchoring activated PKC isozymes, RACKs anchor other signaling enzymes. RACK1, the anchoring protein for activated bIIPKC, binds for example, Src tyrosine kinase, integrin, and phosphodiesterase. RACK2, the ePKC-speci®c RACK, is a coated-vesicle protein and thus is involved in vesicular release and cell ± cell communication. Therefore, RACKs are not only adaptors for PKC, but also serve as adaptor proteins for several other signaling enzymes. Because at least some of the proteins that bind to RACKs, including PKC itself, regulate cell growth, modulating their interactions with RACKs may help elucidate signaling pathways leading to carcinogenesis and could result in the identi®cation of novel therapeutic targets. Oncogene (2001) 20, 6339 ± 6347.
Work in the past few years demonstrates that temporal and spatial regulation of signal transduction is obtained by placing signaling enzymes from the same or from dierent pathways in close proximity, within signaling complexes (Burack and Shaw, 2000; Hubbard and Cohen, 1993; Mochly-Rosen, 1995; Pawson and Scott, 1997) . Binding of signaling enzymes to such complexes is often dependent on cell stimulation and is mediated by proteins that are collectively termed adaptor proteins or adaptors. Adaptors are usually devoid of catalytic activity, but contain at least two domains that mediate protein ± protein interactions ( Figure 1 ). Adaptors can connect between a signaling enzyme and a particular organelle or site in the cell ( Figure 1a) ; in that case adaptors anchor the signaling enzyme at a particular site, next to a substrate and/or away from enzymes with opposing functions. Adaptors may concomitantly bind several signaling enzymes (Figure 1b) . If the enzymes modulate each other's function, binding of both enzymes to one adaptor provides an eective way to obtain dierent outcomes in signal transduction. This context-dependent signal transduction is an essential means by which cells handle multiple stimuli (Burack and Shaw, 2000; Hubbard and Cohen, 1993; Mochly-Rosen, 1995; Pawson and Scott, 1997) . Therefore, elucidating the molecular nature of the interaction of each signaling protein with its adaptor(s) is required for understanding individual signaling pathway and the responses of the cells to both single and multiple stimuli.
Here, we focus on one family of adaptors, termed RACKs (receptors for activated C-kinase), that participate in protein kinase C (PKC) signaling. First, the evidence that speci®city of PKC-mediated signaling is provided by anchoring of activated PKC to its speci®c RACK will be discussed. We will then review data on the role of RACKs as adaptors for enzymes of other signaling pathways. Next, we describe studies suggesting a role for PKC and RACKs in cancer. Finally, using our work on inhibitors and activators of PKC binding to RACKs, as an example, we will discuss how modulation of binding to adaptor proteins may lead to the design of drugs that interfere with speci®c cellular functions.
Speci®city of PKC-mediated signaling is provided by anchoring of activated PKC isozymes to their speci®c RACKs
There are at least 10 dierent PKC isozymes that can be further divided into at least three subfamilies according to their sensitivity to the second messengers, calcium and diacylglycerol (DAG), or to PMA, which can substitute for DAG. The classical cPKC isozymes (a,bI, bII, and gPKC) are sensitive to both second messengers and to PMA. The novel PKC isozymes (d, e, Z, and yPKCs) are activated in the presence of DAG or PMA alone. The atypical PKC isozymes (z and l/i) depend on lipids, but are not activated by DAG, calcium or PMA (Mellor and Parker, 1998; Nishizuka, 1988) . Despite the extensive sequence and structural homologies between dierent PKC isozymes, especially within the catalytic domain, individual PKCs mediate unique cellular functions (Dempsey et al., 2000; Jaken and Parker, 2000) , presumably determined by the substrates that they phosphorylate (Carpenter et al., 1987; Parker et al., 1989) .
Immuno¯uoresence studies demonstrate that activation of PKC is accompanied by movement or translocation of each PKC isozyme to a dierent cell compartment. Unique subcellular localization of different activated PKC isozymes was observed in a variety of cell types including GH4C1 rat pituitary cells (Kiley et al., 1990) , primary cultured heart cells (Disatnik et al., 1994a; Mochly-Rosen et al., 1990) , a breast cancer cell line (Disatnik et al., 1994c) and HL60 human promyelocytic leukemia cells (Hocevar and Fields, 1991) . It therefore appears likely that localization of activated PKC isozymes to dierent subcellular sites confers speci®c substrate phosphorylation and dierent cellular responses. We proposed that isozyme-selective anchoring proteins, termed collectively RACKs, for receptors for activated C-kinase, bind individual PKC isozymes following their activation. Binding to its respective RACK localizes each PKC isozyme next to a subset of protein substrates and away from others and thus bestows dierent functional speci®city for each activated isozyme (Mochly-Rosen, 1995) .
In the following, we focus on RACK1, the selective RACK for bIIPKC (Ron et al., 1994) , and RACK2 (previously identi®ed as b`COP' (Harrison-Lavoie et al., 1993; Stenbeck et al., 1993) ), the selective RACK for ePKC (Csukai et al., 1997) . Both RACKs contain seven repeats of the WD40 motif, ®rst identi®ed in the b subunit of the heterotrimeric G protein, Gb (Fong et al., 1987) . bIIRACK, RACK1, and eRACK bind their respective isozymes in a selective and saturable manner (Csukai et al., 1997; Ron et al., 1994) . In addition, RACK1 and eRACK are not substrates for PKC, but in their presence, substrate phosphorylation by the corresponding PKC isozyme is increased by severalfold (Csukai et al., 1997; Ron et al., 1994) . Finally, RACK1 and bIIPKC and eRACK and ePKC are colocalized, respectively (Csukai et al., 1997; and each isozyme and its RACK can be coimmmunoprecipitated only after PKC activation of cells by PMA or hormone receptor coupled to generation of DAG (Csukai et al., 1997; Rodriguez and Mochly-Rosen, submitted) .
Regulation of RACK expression by PKC
The expression of RACKs appears to be tightly regulated . Multiple attempts to make a stable cell line expressing RACK1 in several labs have failed. Recently, Ping and collaborators have demonstrated that a 10-fold over-expression of ePKC increases eRACK expression by 70% (Pass et al., 2001) . Interestingly, further over-expression of ePKC to a 40-fold over basal results in an increased level of both eRACK protein levels (a threefold increase) and RACK1 protein levels (75% increase) and association of ePKC with the bIIPKC-selective, RACK1 (Pass et al., 2001) . In addition to demonstrating the connection between the expression of ePKC and its RACK, these ®ndings illustrate a common pitfall when proteins are over-expressed, a technique often used in studies of signaling enzymes in cancer (see below). The introduced change is rarely the only one to occur; often compensatory responses take place to correct for the imbalance. Moreover, because, as discussed in the following, RACKs bind proteins other than PKC, these over-expression studies should be interpreted with caution, as proteins other than the one over-expressed may contribute to the studied phenotype.
The role of RACKs as adaptors of other signaling enzymes
As discussed above, both RACK1 and RACK2 contain seven repeats of the WD40 motif (Csukai et al., 1997; Ron et al., 1994) , a domain involved in protein-protein interaction (Neer et al., 1994) . It was therefore expected that more than one protein could bind to RACKs through these interaction domains. In the following, we describe some of the studies demonstrating that both RACK1 and eRACK serve as adaptors for multiple signaling enzymes and therefore may organize signaling complex (Figure 2 ).
Phospholipase Cg (PLCg)
We found that at least part of the RACK1-binding site in PKC is localized to the C2 domain . Because phospholipase Cg (PLCg), a signaling Figure 1 The role of adaptor proteins in localizing signaling enzymes. (a) Shown is an adaptor protein (hatched), anchoring an enzyme (gray) to a particular subcellular site, next to a speci®c substrate (white). In that case, the adaptor may facilitate ecient phosphorylation of a rare substrate or of a substrate for which the kinase has low anity. (b) Shown is an adaptor that anchors two enzymes (A and B). One or both enzymes may exert catalytic activity on the other (e.g. kinase activity). In that case, anchoring to an adaptor serves to alter the catalytic activity or speci®city of the modi®ed enzyme, and may thus increase the repertoire of the enzyme's function. The same adaptors may bind only one or several signaling enzymes at the same time. Adaptors may themselves be modi®ed by the enzymes that bind to them and therefore their own roles may be altered by speci®c signaling events. The review provides examples to all of the above enzyme that generates DAG when cells are activated by growth factor receptors also contains a C2 domain, we determined whether PLCg also binds to RACK1 (Disatnik et al., 1994b) . PLCg binding to a puri®ed bRACK of 32 kDa (presumably RACK1) increased when cells were activated by epidermal growth factor (EGF) (Disatnik et al., 1994b) . Moreover, in vitro phosphorylation of PLCg on tyrosine residues by EGF receptor, which increases PLCg activity, also increased binding of PLCg to RACK1 (Disatnik et al., 1994b) . Therefore, RACK1 may localize bPKC next to activated PLCg, the upstream enzyme that generates the PKC activator, DAG, thus providing a means for ecient EGF-induced activation of PKC-mediated signaling.
ras-GAP
The activation of ras, a key protein in the regulation of cell growth and a protooncogene itself, is terminated by the breakdown of bound GTP to GDP. This reaction is enhanced by the p120 GTPase activating protein, GAP (van der Geer et al., 1997). Because similar to PKC and PLCg, GAP also contains a C2 domain, we determined whether GAP also binds to RACK1. These studies demonstrated that GAP binds to RACK1 in a saturable manner. However, although the C2 domain facilitates the translocation of GAP in response to calcium (Gawler et al., 1995) , a fragment of GAP lacking the C2 domain still binds to RACK1 (Disatnik and Mochly-Rosen, unpublished results) , suggesting that other domains in GAP mediate RACK1-binding. As discussed below, Cartwright and collaborators found that the GAP fragment containing the SH2 domain is one of three out of twelve SH2 domains tested that bind to RACK1 in vitro . Therefore, GAP binds to RACK1 and this binding is likely mediated by multiple binding domains in the protein, including the SH2 domain and possibly the C2 domain.
We noted that GAP and PLCg also contain the pleckstrin homology (PH) domain, a domain that is involved in protein ± protein interactions as well as protein ± lipid interactions (Lemmon et al., 1996) . Moreover, Touhara et al., showed that the Gb subunit, a homolog of RACK1 which is also composed of seven repeats of the WD40 motif (Fong et al., 1987) , binds recombinant fragments containing the PH domain of speci®c signaling enzymes (Touhara et al., 1994) . We therefore used these same recombinant fragments to determine whether RACK1 binds PH domains of dierent signaling enzymes in a selective fashion.
Of several recombinant fragments containing the PH domain, GAP, dynamin-1 and the spectrin PH domains bind to RACK1 to the highest extent (Rodriguez et al., 1999) . No binding of the PH domain of e.g., PLCg, b-adrenergic receptor kinase, or RAC-b PH domains to RACK1 is detected in this assay (Rodriguez et al., 1999) . Finally, a recent study of Koehler and Moran demonstrated GAP associates with RACK1, whereas deletion mutants lacking the PH or C2 domain of GAP do not (Koehler and Moran, 2001) . Moreover, there is a consensus PKC phosphorylation site next to the PH domain of GAP and once PKC phosphorylates that site, the anity of GAP for RACK1 is decreased (Koehler and Moran, 2001) . These data suggest that a trimolecular complex between PKC, GAP, and RACK1 occurs, which may serve to bring GAP, a PKC substrate, in close proximity to activated bIIPKC. However, studies on the functional consequences of this interaction on GAP function and the function of other PH domaincontaining proteins in cells are required to directly examine this possibility.
Dynamin-1
The PH domain of dynamin-1, another PKC substrate (Robinson et al., 1993) , also binds to RACK1 (Rodriguez et al., 1999) . We used this interaction to examine the functional consequences of RACK1-binding to signaling proteins other than PKC and the cross-talk between these signaling pathways. Dynamin-1 is a protein involved in clathrin-coated vesicle recycling (De Camilli et al., 1995) . We found activation-dependent formation of a complex of bIIPKC, RACK1, and dynamin-1 in cells. RACK1 increases the intrinsic GTPase activity of dynamin-1 over sixfold in vitro and cooperatively enhances the ability of bIIPKC to phosphorylate dynamin-1. In addition, expression of a membrane-targeted form of RACK1 containing the farnesylation sequence CAAX (Cys-Val-Ile-Met), signi®cantly impairs dynamin-1-dependent uptake of transferrin (Rodriguez and Mochly-Rosen, submitted). These data indicate that Figure 2 RACK1 as an adaptor for multiple signaling enzymes. RACK1, initially described as a bIIPKC-speci®c anchoring protein (Ron et al., 1994) and an adaptor, binds many other signaling enzymes (see text). Here, we use RACK1 crystal structure (center), modeled after that of its homolog, Gb subunit (Garcia-Higuera et al., 1996; Sondek et al., 1996; Wall et al., 1995) . The interaction sites for all the signaling enzymes on RACK1 have not yet been mapped. However, because RACK1 contains seven equivalent WD40 domains, this drawing depicts RACK1 concomitantly binding seven dierent signaling enzymes (1 ± 7), each on a dierent WD40 domain. Currently, there is only evidence for concomitant binding of two signaling enzymes at the same time (see text) RACK1 anchored to the membrane stimulated dynamin-1 GTPase activity prematurely. Together, these data implicate RACK1 not only as an adaptor that colocalizes PKC with its substrate, dynamin-1 ( Figure  1a ), but also as a direct modulator of the enzymatic activity of dynamin-1 (Table 1 ; Rodriguez and MochlyRosen, submitted).
Src c-Src is a tyrosine kinase protooncogene involved in regulation of growth and dierentiation (Moasser et al., 1999) . Activated Src is found in dierent types of cancer including breast cancer and colon cancer (Irby and Yeatman, 2000) and is required to maintain the neoplastic phenotype (Irby and Yeatman, 2000) .
Connection between Src and PKC has been demonstrated in Swiss 3T3 cells, where activation of PKC by phorbol ester was shown to stimulate Src activity (Rodriguez-Fernandez and Rozengurt, 1996) . A molecular basis for the regulation of Src by PKC is suggested by the recent work of Cartwright and collaborators (Chang et al., 2001 . Using a two-hybrid screen, these authors showed that the SH2 domain of c-Src binds directly to RACK1 and binding of Src to RACK1 is increased after phosphorylation of a tyrosine in the sixth WD40 domain of RACK1 (Chang et al., 2001) . Full-length cSrc co-precipitates with RACK1 and the two proteins are co-localized when NIH3T3 cells are stimulated with PMA (Chang et al., 2001) . Moreover, Src activity in vitro is inhibited by 50% in the presence of RACK1 and there is a decreased tyrosine phosphorylation and in cell proliferation in cells over-expressing RACK1 . Finally, although Src binding to RACK1 in vitro is independent of PKC association to RACK1, the Src-RACK1 interaction in cells is enhanced by PKC activation induced by PMA treatment (Chang et al., 2001) . Therefore, a cross-talk between tyrosine kinase pathway and a serine/threonine kinase pathway may occur by binding of the two kinases to the same adaptor, RACK1.
PTPm
A yeast two-hybrid screen demonstrated that RACK1 also associates with the receptor protein tyrosine phosphatase, PTPm (Mourton et al., 2001 ). PTPm and RACK1 interact when over-expressed in insect cells using the baculovirus expression system. Importantly, the interaction of PTPm with RACK1 is disrupted if constitutively active Src is co-expressed, suggesting that the binding of PTPm and Src to RACK1 is mutually exclusive (Mourton et al., 2001) . As MV 1 Lu mink lung epithelial cells are cultured to a higher density, these authors observed an increase in the association of endogenous RACK1 and PTPm, especially noted at cell-cell contact points (Mourton et al., 2001) . These data suggest that PTPm can recruit RACK1 to that site to regulate the response to cell adhesion in normal cell growth; thus inhibition of the PTPm-RACK1 interaction by v-Src could contribute to the transformed phenotype by disrupting cell ± cell adhesion.
Integrins
RACK1 also binds the integrin b subunit as demonstrated using a two-hybrid screen (Liliental and Chang, 1998) . This integrin subunit is important in activationdependent cell adhesion (Reszka et al., 1992) . Integrin b subunit binds to RACK1 in vitro. However, in cells, interaction of integrin with RACK1 is dependent on stimulation by PMA (Liliental and Chang, 1998) . In these cells, PMA induces PKC activation and cell spreading (Liliental and Chang, 1998) and the integrin b subunit becomes phosphorylated (Hibbs et al., 1991) . Therefore, RACK1 may be a regulator of cell adhesion by co-localizing PKC and its substrate, integrin b.
Phosphodiesterase 4D5
A yeast two-hybrid screen also demonstrated that RACK1 binds the cAMP phosphodiesterase isoform 4D5 (PDE4D5) (Yarwood et al., 1999) . The interaction was con®rmed by co-immunoprecipitation of PDE4D5 with native RACK1 in Cos7 cells. No binding is observed with other WD40 proteins including eRACK (Yarwood et al., 1999) . Although, interaction of PDE4D5 with RACK1 is not aected by PMAstimulation of the cells, binding of PDE4D5 to RACK1 increases the sensitivity of the enzyme to its inhibitor, rolipran (Yarwood et al., 1999) . These data suggest that RACK1 anchors PDE4D5 to speci®c subcellular sites (presumably to confer its phosphodiesterase activity to that site [ Figure 1a] ). In addition, the data also suggest that binding of PDE4D5 to RACK1 caused a conformational change in the enzyme, which may alter its catalytic activity (Table  1 ). The consequences of anchoring of PDE4D5 via RACK1 on cellular functions, in general, and on cell growth, in particular, have not yet been determined. However, other studies indicate that increases in cAMP (Srivastava et al., 1999) and leukemic cells (Myklebust et al., 1999; Thompson et al., 1999) .
Viral proteins
At least two studies demonstrated that RACK1 also interacts with viral proteins. The in¯uenza A virus M1 protein interacts with RACK1 and is phosphorylated by PKC in cell extracts (Reinhardt and Wol, 2000) . RACK1 also interacts with the Epstein-Barr virus activator protein, BZLF1, a member of the AP-1 transcription factor protein family which is also phosphorylated by PKC (Smith et al., 2000) . Because Epstein-Barr virus is associated with dierent lymphoid and epithelial cell malignancies in humans (Kie, 1996) , the data suggest that regulating RACK1 interaction with this viral immediate-early gene may alter the outcome of the viral infection.
eRACK also binds proteins other than ePKC
There is less evidence for the possible role of eRACK (b'COP) as an adaptor protein for other signaling enzymes. However, eRACK is part of the coatomer complex, COPI, and therefore binds to a number of other proteins. eRACK/b'COP binds the small ras-like GTPase, ARF, in its GTP-bound form (De Matteis et al., 1993) . The GTP-GDP cycle of ARF is linked to COPI recruitment, vesicle binding, and uncoating (De Matteis et al., 1993) . We have shown that increased binding of eRACK to Golgi membranes in the presence of GTPgS is associated with an increase in ePKC binding (Csukai et al., 1997) . Moreover, treatment with brefeldin A, a disruptor of Golgi organization, blocks ePKC binding to Golgi membranes. Binding of ePKC to eRACK is therefore aected by factors which in¯uence the binding of this RACK to Golgi membranes, demonstrating a crosstalk between signaling events involved in PKC activation and those involved in vesicular release.
Adaptor proteins are essential components in signal transduction
The role of RACKs as adaptors for multiple signaling enzymes from diverse signaling pathways is not unique. Work in the past few years demonstrates that temporal and spatial regulation of signal transduction can be achieved by placing multiple signal transduction enzymes from the same or dierent pathways in signaling complexes by anchoring them via one or more adaptor (Burack and Shaw, 2000; Kholodenko et al., 2000; Mochly-Rosen, 1995; Pawson and Scott, 1997) (Figure 2) . What is the role of adaptors in signaling complex formation? This process, involving multiple protein-protein interactions can modulate the speci®city of the bound enzymes and thus increases the repertoire of their functions. By direct association to the same adaptor, speci®c enzymes are placed in close proximity to a subset of substrates, eectively increasing the anity of the anchored enzymes for these substrates. In those cases, adaptor proteins coordinate physical association between enzymes and substrates and thus act as catalysts for speci®c reactions ( Figure  1b) . Adaptors can also anchor signaling enzymes next to their upstream regulators, as was demonstrated in the MAP kinase cascade in yeast (reviewed by Levin and Errede, 1995) ). Ste5 binds Ste11 (MEKK), Ste7 (MEK), and Fus3 (MAPK) in a yeast two-hybrid assay. Ste5 also copuri®es with Ste11, Fus3, and a hypophosphorylated form of Ste7, and all four proteins co-sedimented in a glycerol gradient as if in a large complex (Choi et al., 1994) . Therefore, in this example, activation of an enzyme cascade is coordinated by physically con®ning the signaling enzymes to a single subcellular site. Once the downstream enzymes are activated, they may detach from the complex and diuse to a new site where they carry out other functions.
In addition to increasing the eective concentration of the substrate or the activator of a particular signaling enzyme, binding of an enzyme to an adaptor can increase, decrease or not alter the intrinsic catalytic activity of that enzyme. Some of these eects are summarized in Table 1 , for RACK1 binding of signaling enzymes. Adaptors can also provide coordinated anchoring of enzymes with similar or even opposing roles to provide ®ne-tuning for signaling events. We discussed earlier evidence that RACK1 anchors both the tyrosine kinase, c-Src, and the tyrosine phosphatase, PTPm. If these two enzymes act on the same substrate, anchoring of the kinase and phosphatase at various ratios, can lead to opposing eects.
Finally, adaptors can also provide a`raft' which moves a signaling complex from one site to another, in a constitutive or regulated manner. The ®rst evidence for the role of RACK1 as a raft or shuttling protein was provided by the work of Ron et al. (1999) . They found that a one-minute treatment of CHO cells over-expressing the dopamine receptor with a dopamine receptor agonist or with PMA caused translocation and co-localization of RACK1 and bIIPKC in the cell periphery. After 10 min, however, the RACK1-bIIPKC complex is found at the perinuclear area of the cell, the ®nal location of activated bIIPKC in these cells . Therefore, RACK-associated with bIIPKC and possibly with some other signaling enzymes can move as a complex from one cellular site to another, likely resulting in dierent molecular events at each site depending on available substrate.
The role of PKC and RACKs in cancer
The involvement of PKC in cancer has been predicted since the ®nding of Castagna et al. (1982) that the tumor promoter phorbol ester, PMA, activates these second messenger-dependent protein kinases. Subsequent data from multiple studies suggest that PKC-mediated signaling plays a role in a variety of cancers. For example, in malignant breast tumors, PKC activity is elevated compared with normal breast tissue (Vallete et al., 1987) and there is an inverse relationship between the level and activity of PKC and the level of estrogen receptor, which, in turn, is directly correlated with the prognosis Wyss et al., 1987) . PKC activity and/or amounts have also been shown to correlate with invasiveness of breast cancer cell lines; in cells with dierent metastatic potentials, motility and invasiveness appears to correlate with PKC activity (Kiley et al., 1999a,b) . PKC levels also correlate with malignancy in other tumors including bladder carcinoma (Schwartz et al., 1993) , colon carcinoma (Gokmen-Polar et al., 2001), pituitary tumors (Maeda and Lloyd, 1993) , and hepatocellular carcinoma (Tsai et al., 2000) . RACK1 levels are altered in some cancers; RACK1 is *fourfold higher in human non-small cell lung carcinoma as compared with normal lung tissue and approximately 20-fold higher in colon carcinoma as compared to normal colon (Berns et al., 2000) . However, there is no signi®cant increase in RACK1 mRNA in breast carcinoma (Berns et al., 2000) . Although changes in PKC (and sometimes in RACK1) are noted in cancer, it is not clear whether PKC signaling contributes to the phenotype, or whether changes in PKC or RACKs constitutive compensatory responses counteracting the phenotype.
Over-expression of PKC is often used to address this question and assess the potential role of PKC in cell functions related to abnormal cell growth and transformation. Using this approach, several PKC isozymes have been implicated in regulating cell cycle. However, often-con¯icting ®ndings on the role of individual isozymes have been reported. For example, ZPKC expressed in NIH3T3 cells delays G1/S transition (Livneh et al., 1996) , whereas, in smooth muscle cells, a and/or ePKC appear to mediate this function (Sasaguri et al., 1993) . Similarly, there are con¯icting data on the role of PKC in progression from G2/M. In HL60 cells, bIIPKC is required for this process (Thompson and Fields, 1996) , whereas, in CHO cells, dPKC activation induces G2/M arrest (Watanabe et al., 1992) . In several systems, PKC isozymes have opposing functions in the same cell in response to the same stimulation. For example, overexpression of aPKC inhibits E2F activity (a protein involved in cell cycle progression) whereas overexpression of dPKC or ePKC enhances it (Nakaigawa et al., 1996) . Together these data suggest a regulatory role for PKC in cell growth and dierentiation possibly in a tissue-speci®c manner. However, a direct demonstration of a role for individual isozymes in these processes and their contribution to cell transformation requires the use of isozyme-selective inhibitors and activators.
Modulation of binding to adaptor proteinsÐ a therapeutic opportunity?
Our work focused on the interaction of PKCs with their RACKs, although interference with protein ± protein interaction could be used for the study of any enzyme binding to its adaptor protein. Because interaction of each PKC isozyme with its RACK is required for its selective function, we set out to identify selective agonist and antagonists of this interaction. We ®rst identi®ed the binding sites on the two proteins and showed that short peptides corresponding to these binding sites serve as isozyme-selective competitor inhibitors of PKC translocation and function ( Figure  3a and see below). In that case, the adaptor-binding site on the enzyme is engaged in an intramolecular interaction with a pseudo-adaptor sequence, when the enzyme is inactive (step 1). However, this intramolecular interaction is occasionally disrupted even in the absence of an activating stimulus (step 2a). The peptide corresponding to the site in the enzyme that is engaged in the intramolecular interaction is termed pseudo-adaptor peptide. It is also homologous, but dierent in a critical way, from the sequence in the adaptor that binds the enzyme (enzyme-binding site; step 3). If the pseudo-adaptor peptide is introduced into cells, it binds to the transient`open' form of the enzyme (step 2b), and stabilizes the open form. Because the anity of pseudo-adaptor peptide is lower than that of the true binding-site on the adaptor, when the pseudo-adaptor peptide leaves the enzyme, the enzyme binds the adaptor (step 3). Using this approach, we have identi®ed isozymeselective activators, or pseudoRACKs, for bPKC and for ePKC (Dorn et al., 1999) . For more details see the text and (Souroujon and Mochly- Peptides that induce binding of PKC isozyme to its RACK in the absence of second messenger generation were also identi®ed. These activator peptides, collectively termed pseudo-RACK peptides, are derived from a sequence in PKC that shares homology with its corresponding RACK (Dorn et al., 1999; Souroujon and Mochly-Rosen, 1998) . However, there is a charge dierence between the pseudo-RACK sequence and the corresponding sequence of the PKC-binding site on RACK. We proposed that the pseudo-RACK sequence in each PKC isozyme mediates intramolecular interaction within the enzyme, covering the RACK-binding site in the inactive enzyme (Figure 3b, step 1) . Following activation, the intramolecular interaction is replaced with the more favored intermolecular interaction between the RACK-binding site on PKC and the PKC-binding site on its RACK (Souroujon and Mochly-Rosen, 1998) (Figure 3b, step 3) . The intramolecular interaction within PKC is spontaneously disrupted at a slow rate (Figure 3b, step 2a) . We suggest that in the presence of the pseudo-RACK peptide (Figure 3b, step 2b) , binding of the peptide to the enzyme in this transient form may stabilize it, leaving the RACK-binding site exposed. In the presence of RACK, the peptide is replaced with the higher anity binding protein (Figure 3b, step 3) , resulting in binding of PKC to its RACK and stabilization of the activated enzyme (Figure 3b, step  3) .
We found that peptides corresponding to the pseudo-RACK sequence activates PKC in vitro and induces PKC translocation and function in cells (Chen and Mochly-Rosen, 2001; Dorn et al., 1999; and in vivo (Dorn et al., 1999) , in an isozyme-selective manner. Similarly, peptide translocation inhibitors inhibit the translocation and function of PKC in an isozyme-selective manner (Aley et al., 2000; Chen and Mochly-Rosen, 2001; Gray et al., 1997; Hu et al., 2000; Hundle et al., 1997; Johnson et al., 1996a; Liu et al., 1999; Mayne and Murray, 1998; Mochly-Rosen et al., 2000; Yedovitzky et al., 1997; Zhang et al., 1997 (see below) ).
The peptide translocation inhibitors and activators that we have identi®ed are 6 ± 8 amino acids long. Although they are not cell permeable, a variety of methods are now available to introduce peptides into living cells. These include microinjection , transient permeabilization Johnson et al., 1996a,b) , use of cell permeable carrier peptides (Chen and Mochly-Rosen, 2001; Dorn et al., 1999) , and expressing the peptides in transgenic mice (Dorn et al., 1999; Mochly-Rosen et al., 2000) or by transient or stable transfection of such genes in cells (Hundle et al., 1997) .
The ®rst translocation inhibitor peptide derived from a RACK-binding site on PKC was bC2-4, a peptide derived from the C2 domain of bPKC . bC2-4 selectively inhibits translocation of the C2-containing isozymes, bI and bIIPKC in cardiac myocytes and L-type calcium channel inhibition by PMA in cardiac myocytes (Zhang et al., 1997) . bC2-4 also selectively inhibits insulin-induced nuclear envelop breakdown and Xenopus oocyte maturation whereas the pseudo-RACK, the bPKC activator, which activates both bI and bIIPKC, induces maturation in the absence of insulin, demonstrating a critical role for bPKC in this function . Recently, Wu and collaborators have used bC2-4 to determine the role of bPKC in mesangial cell proliferation . This peptide inhibited proliferation mediated by endothelin . In contrast, bC2-4 did not aect proliferation induced by epidermal growth factor, thrombin or phorbol esters, suggesting a speci®c role for bPKC in endothelin-mediated proliferation of these cells .
Similarly, a RACK-binding site on ePKC is also found within a C2-like domain found in the ®rst variable domain (V1) of all the nPKCs (Mellor and Parker, 1998; Nishizuka, 1988) . eV1-2 (amino acids 14 ± 21), a peptide derived from this domain, selectively inhibits ePKC translocation by binding to eRACK in several model systems. These include neonatal (Johnson et al., 1996a) and adult rat cardiac myocytes in culture , adult mouse heart, and in vivo (Dorn et al., 1999; Mochly-Rosen et al., 2000) . We showed that ePKC mediates PMA-induced inhibition of spontaneous contraction rate of cardiac myocytes (Johnson et al., 1996a; Johnson and Mochly-Rosen, 1995) . dPKC is also activated in these cells. However, in contrast to ePKC, using dPKC-speci®c inhibitor derived from the V1 region of this isozyme, it was found that dPKC mediates increase in contraction rate in the same cells (Csukai and Mochly-Rosen, 1999; Johnson et al., 1996a) . Protection of cardiac myocytes from ischemia-induced cell death is also mediated by ePKC; eV1-2 inhibits cardioprotection induced by hormone or preconditioning . Although ePKC is one of two isozymes that are activated by this process, activation of ePKC alone, using the ePKC-speci®c activator, pseudo-eRACK, is sucient to render the cells resistant to ischemia in vitro and in vivo (Dorn et al., 1999) .
A role for ePKC interaction with its RACK in cancer has also been demonstrated. Mayne and Murray showed that apoptosis of a histiocytic lymphoma cell line, U937, is induced by TNFa or calphostin (a PKC inhibitor) and this eect is blocked by the PKC activator, TPA (Mayne and Murray, 1998) . By selectively inhibiting ePKC translocation using the eV1-2 peptide, this anti-apoptotic eect of TPA is blocked (Mayne and Murray, 1998 ). These data demonstrate that ePKC is required for the protective eect of TPA in TNFa-induced apoptosis, suggesting that ePKC may play a role in survival of leukemic cells (Mayne and Murray, 1998 ).
An opposite role for ePKC has been found in human thyroid tumors. An ePKC translocation inhibitor is found in a human thyroid carcinoma cell line, WRO (Knauf et al., 1999) . Using positional cloning, Fagin and collaborators identi®ed a rearrangement and ampli®cation of the 2p21 locus in 28% of thyroid neoplasms. In WRO cells, ampli®cation of this locus results in expression of the N-terminal fragment of ePKC (amino acids 1 ± 117) (Knauf et al., 1999) . This fragment contains the majority of the translocation inhibitory fragment of ePKC, eV1 (amino acids 1 ± 142), that was used by Johnson and Mochly-Rosen (1995) to inhibit ePKC translocation and function (Johnson et al., 1996a) . This fragment also contains the ePKC-selective translocation inhibitor peptide, eV1-2 (amino acids 7 ± 14) Johnson et al., 1996a) . As expected, ePKC translocation is inhibited in WRO cells (Knauf et al., 1999) . Moreover, reduced activity and translocation of ePKC is found in multiple other spontaneously occurring human thyroid follicular carcinomas as well as in human papillary carcinoma of the thyroid (Knauf et al., 1999) . Together, these results suggest that ePKC may play an important role in preventing the generation of these types of thyroid tumors.
In summary, many studies suggest that the regulation of both PKC isozymes and their corresponding RACKs is altered in the neoplastic process. Therefore, agents that selectively interfere with or induce these PKC-RACK interactions may provide a new therapeutic for cancer. Because RACKs are also adaptor proteins for several other signaling proteins that can modulate the neoplastic process, regulation of their interaction with RACKs may also provide a useful target for new drug development for the treatment or prevention of cancer.
